Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
INNOVUS PHARMACEUTICALS, INC. (INNV) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/14/2020 8-K Quarterly results
02/14/2020 8-K Quarterly results
09/18/2019 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among Aytu BioScience, Inc., Aytu Acquisition Sub, Inc. and Innovus Pharmaceuticals, Inc",
"Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals"
08/13/2019 8-K Quarterly results
Docs: "Innovus Pharma Reports Quarterly Revenue for the Second Quarter 2019 of $6.8 million, a 27.7% Increase from Prior Quarter Sales & Marketing Expense as a Percentage of Total Revenue Declined to 41.7% for the three months ended June 30, 2019 Compared with 75.6% in Comparable Period in the Prior Year Reduced Operating Loss by 21% Compared with both the Prior Quarter and Comparable Quarter in the Prior Year SAN DIEGO, August 13, 2019 – Innovus Pharmaceuticals, Inc. , an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, announced today its reported results for the second quarter ended June 30, 2019. Financial highlights for the second qua..."
07/24/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/22/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Innovus Pharma Investor Relations"
06/19/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Corporate Update"
05/31/2019 8-K Investor presentation
Docs: "Corporate Presentation"
05/30/2019 8-K Submission of Matters to a Vote of Security Holders
05/15/2019 8-K Quarterly results
Docs: "Innovus Pharma Reports Quarterly Revenue for the First Quarter 2019 of $5.4 million, a 18.0% Increase From Comparable Quarter in the Prior Year Cash, inclusive of merchant processor holdback, of $2.9 million as of May 13, 2019 SAN DIEGO, May 15, 2019 – Innovus Pharmaceuticals, Inc. , an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’ s and women's health and respiratory diseases, announced today its reported results for the three months ended March 31, 2019. Financial highlights for the three months ended March 31, 2019 compared to March 31, 2018 included: ■ Revenues of approximately $5.4 million, an increase of $0.8 million or 18.0% compared to prior year and $0.6 milli..."
04/19/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Innovus Pharma Investor Relations"
04/11/2019 8-K Investor presentation
Docs: "Corporate Presentation"
04/01/2019 8-K Quarterly results
Docs: "Innovus Pharma Reports Record Annual Revenue for Fiscal 2018 of $24.0 million in line with Previous Guidance and Product Gross Margins of 81%"
03/15/2019 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Certificate of Amendment to the Amended and Restated Articles of Incorporation"
02/26/2019 8-K Quarterly results
01/07/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Form of Securities Purchase Agreement and disclosure schedules thereto"
12/31/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Warrant",
"Form of Securities Purchase Agreement and disclosure schedules thereto",
"Form of Registration Rights Agreement",
"Letter Agreement by and between the Company and H.C. Wainwright & Co., LLC",
"INNOVUS PHARMACEUTICALS ANNOUNCES $3.17 MILLION Private placement San Diego, CA, December 31, 2018 -- Innovus Pharmaceuticals, Inc. , an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’ s and women's health and respiratory diseases, today announced that it has entered into a definitive agreement with a healthcare-dedicated institutional investor for the sale of 45,306,347 shares of common stock , series A warrants to purchase up to 45,306,347 shares of common stock and series B warrants to purchase up to 45,306,347 shares of common stock in a private placement at a price of $0.07 per share and associated warrants for gross proceeds of approximately $3.17 million. The transactio..."
11/14/2018 8-K Quarterly results
Docs: "Innovus Pharma Reports Another New Quarterly Revenue Record of Approximately $7.4 million for the Third Quarter 2018 and $19.2 million for the First Nine Months of 2018"
08/31/2018 8-K Investor presentation
Docs: "Corporate Presentation"
08/10/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "ADDITIONAL EXHIBITS"
07/17/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Innovus Pharmaceuticals Reports Preliminary Q2 2018 Sales Revenue of $6.6 million to $6.8 million Preliminary Quarterly Revenue Increase of 47-51% and Comparable 2017 Second Quarter Increase of 330-340% and Fiscal Year 2018 Net Revenue Annual Guidance Adjusted Upwards to at Least $22 Million SAN DIEGO, July 17, 2018 – Innovus Pharmaceuticals, Inc., , today announced preliminary second quarter 2018 net revenue is estimated to be between $6.6 million to $6.8 million or an approximate 47-51% increase from the first quarter of 2018 and an approximate increase of 330-340% from the second quarter of 2017. Innovus Pharma's second quarter 2018 anticipated revenue results are preliminary and based on the most current information available and are subject to completion of the condensed consolidated ..."
05/30/2018 8-K Investor presentation
Docs: "Corporate Presentation"
05/29/2018 8-K Submission of Matters to a Vote of Security Holders
05/14/2018 8-K Quarterly results
04/23/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EMPLOYMENT AGREEMENT, DATED APRIL 27, 2018"
04/06/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/02/2018 8-K Quarterly results
Docs: "Innovus Pharmaceuticals Reports Record Annual Revenue for Fiscal 2017 of $8.8 Million, Preliminary Q1 2018 Revenue of $4.3 million to $4.4 million and Expects to Exit 2018 Profitable Year over Year Revenue Increase of 83% with Reduction in Net Loss of 53% in 2017 and Fiscal Year 2018 Net Revenue Annual Run Rate of At Least $18 million SAN DIEGO, April 2, 2018 – Innovus Pharmaceuticals, Inc., , today announced full year 2017 net revenue of $8.8 million compared to $4.8 million in revenue for the same period in 2016 and fourth quarter of 2017 net revenue of $2.4 million compared to $1.7 million in revenue for the same period in 2016. Preliminary first quarter 2018 net revenue is estimated to be between $4.3 million to $4.4 million or an approximate 85% increase from the fourth quarter of 201..."
01/23/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Innovus Pharma Signs Exclusive License and Distribution Agreement with Lavasta Pharma for ProstaGorx® in Certain Middle Eastern and North African Countries The Company to Receive an Upfront Payment plus Transfer Price on Minimum Annual Purchases Requirements"
01/08/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "PRESS RELEASE ISSUED JANUARY 8, 2018."
11/14/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "Innovus Pharma Launches FlutiCare™ OTC Nasal Spray Allergy Relief in the U.S. Product Currently Expected to Generate $10-$15m in Additional Revenues Annually"
09/27/2017 8-K Quarterly results
08/31/2017 8-K Quarterly results
08/14/2017 8-K Quarterly results
06/20/2017 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy